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Abstract: Sitosterolemia is a lipid disorder characterized by the accumulation of dietary xenosterols
in plasma and tissues caused by mutations in either ABCG5 or ABCG8. ABCG5 ABCG8 encodes
a pair of ABC half transporters that form a heterodimer (G5G8), which then traffics to the surface
of hepatocytes and enterocytes and promotes the secretion of cholesterol and xenosterols into the
bile and the intestinal lumen. We review the literature from the initial description of the disease,
the discovery of its genetic basis, current therapy, and what has been learned from animal, cellular,
and molecular investigations of the transporter in the twenty years since its discovery. The genomic
era has revealed that there are far more carriers of loss of function mutations and likely pathogenic
variants of ABCG5 ABCG8 than previously thought. The impact of these variants on G5G8 structure
and activity are largely unknown. We propose a classification system for ABCG5 ABCG8 mutants
based on previously published systems for diseases caused by defects in ABC transporters. This
system establishes a framework for the comprehensive analysis of disease-associated variants and
their impact on G5G8 structure–function.
Keywords: phytosterol; xenosterol; cholesterol; atherosclerosis; gall stone; ABC; transporter
1. Discovery to Therapy
In 1974, Bhattacharyya and Conner described a new lipid storage disorder in two
sisters who presented with tendon and tuberous xanthomas and elevated plasma levels
of phytosterols, sitosterol, campesterol, and stigmasterol [1]. Absorption of radiolabeled
β-sitosterol was reported to be thirty-five times greater than that of normal subjects. They
named their new lipid disorder β-sitosterolemia (hereon referred to as sitosterolemia),
but it would be another 26 years before the discovery of ABCG5 ABCG8 as the causative
gene defect. Subsequent case reports established recessive genetics of the disease and
greatly expanded its potential clinical presentation, which may include elevated low den-
sity lipoprotein (LDL) cholesterol, premature coronary artery disease and death, hemolytic
anemia, macrothrombocytopenia, splenomegaly, adrenal dysfunction, elevated liver func-
tion tests, and cirrhosis [2–13]. Clinical studies in individuals with sitosterolemia revealed
reductions in cholesterol synthesis, biliary cholesterol secretion, plasma clearance, and fecal
elimination of neutral sterols [8,9,14,15]. Despite the absorptive phenotype and metabolism
of phytosterols to bile acids, the clinical management of these patients with low sterol
diets and bile acid binding resins resulted in modest and inconsistent reductions in plasma
phytosterols [5,16].
Following the elimination of key genes in the esterification, absorbance, biosynthe-
sis, and regulation of cholesterol metabolism, the sitosterolemia locus was mapped to a
0.5 centimorgan region on chromosome 2p21 [17,18]. The breakthrough would come two
years later when investigators were studying agonists for liver X receptors (LXR-α NR1H3,
LXR-β NR1H2), sensors of excess cholesterol that promote cholesterol mobilization from
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macrophages, metabolism to primary bile acids, and the excretion of neutral and acidic
sterols [19,20]. A microarray screen of liver and intestinal transcripts from mice treated
with an LXR agonist (T0901317) revealed a modest induction (2.5-fold) of the mouse brown
gene, so named as it is the ortholog of the ABC transporter that determines brown eye
color in Drosophila [21,22]. The human ortholog to mouse brown mapped to 2p21, STSL
(OMIM: STSL1: 210250/STSL2:618666). At virtually the same time, independent groups
identified individuals in multiple kindreds harboring nonsense mutations in either ABCG5
or ABCG8 with sitosterolemia, but not their unaffected family members [22,23]. STSL1 and
STSL2 encode a pair of ATP binding cassette (ABC) half transporters in the G-subfamily.
They reside on opposite strands of the DNA with initiation codons separated by a mere 374
base pairs. In these early reports, transcripts were restricted to the liver and intestine, the
abundance of which increased in response to dietary cholesterol, suggesting the function
of the transporters was to oppose intestinal absorption and promote biliary secretion of
neutral sterols.
The discovery of ezetimibe as the inhibitor of Neiman–Pick C-1-Like 1 (NPC1L1), and
cholesterol absorption was a breakthrough in the clinical management of sitosterolemia [24,25].
Ezetimibe (10 mg/day) was tested as a cholesterol-lowering agent in healthy subjects with
moderate hypercholesterolemia. A detailed analysis of plasma sterols revealed that in addi-
tion to cholesterol, plasma phytosterols were also reduced, indicating that phytosterols and
cholesterol shared a common, ezetimibe-sensitive pathway for absorption, thus suggesting
the drug might be effective in the treatment of sitosterolemia (Figure 1 (1)(2)). Ezetimibe
was subsequently shown to reduce plasma phytosterols in sitosterolemic subjects by >20%
after eight weeks [26]. In a two-year follow-up study, plasma sitosterol and campesterol
levels were reduced by 44% and 51%, respectively [27]. It should be noted that phytosterol
levels in these subjects remained well above normal. However, the reductions observed
with ezetimibe as a single agent or as an adjunctive therapy resolves many of the clinical
manifestations of sitosterolemia (reviewed in [28]).
Figure 1. Enterohepatic sterol flux and regulation of ABCG5 ABCG8. (1) Bile acid micelles facilitate
the solubilization of dietary and endogenous sterols in the proximal small intestine. Phospholipids
not depicted. (2) NPC1L1 facilitates uptake of cholesterol and phytosterols into intestinal enterocytes
(3) Cholesterol is incorporated into chylomicrons, delivered to the plasma compartment through
the lymphatic system, and cleared by the liver. ABCG5 ABCG8 also promotes cholesterol secretion
into the intestinal lumen. (4) Phytosterols are poorly absorbed and largely returned to the intestinal
lumen by ABCG5 ABCG8. (5) Bile acids are reabsorbed in the distal small intestine, stimulate FXR-
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dependent expression of FGF15/19, and are returned to the liver through the portal system. (6) In
the liver, bile acids stimulate ABCG5 ABCG8 catalytic activity and promote the formation of bile acid
micelles that serve as acceptors for ABCG5 ABCG8 mediated biliary cholesterol secretion. (7) Choles-
terol metabolites (oxysterols), through LXR, and bile acids, through FXR and in cooperation with
FGF15/19, activate ABCG5 ABCG8. The half transporters heterodimerize, traffic to the canalicular
surface, and promote biliary phytosterol and cholesterol secretion. (8) Excess cholesterol, phytosterols
and bile acids that are not absorbed/reabsorbed are eliminated from the body.
2. Animal Models of Sitosterolemia
Three independent mouse models of sitosterolemia have been developed which lack
functional ABCG5, ABCG8, or both half transporters [29–31]. In each model, the G5G8
heterodimer is absent. These models largely phenocopy one another and share many
phenotypes with sitosterolemia in humans. These include elevated plasma and tissue levels
of phytosterols, reduced biliary cholesterol, and repression of the cholesterol biosynthetic
pathway. Since the discovery of ABCG5 ABCG8, phenotypes in spontaneous rodent models
have been attributed to defects in either gene or the accumulation of phytosterols. The
Spontaneous hypertensive rat (SHR) harbors a glycine 583 cysteine mutation in ABCG5,
which segregates with elevated phytosterol levels in plasma, but not hypertension [32].
Similarly, a premature stop codon in ABCG5 is present in the thrombocytopenia and
cardiomyopathy (trac) mouse [33]. Plasma phytosterols and platelet counts were rescued
by crossing this strain with mice harboring a human ABCG5 ABCG8 transgene. Mice with a
targeted disruption in either ABCG5 or ABCG8 also display platelet dysfunction, effects that
are reversed with ezetimibe or low phytosterol-containing diets, respectively [34,35]. Other
phenotypes in mice lacking functional G5G8 are reversed by ezetimibe treatment, genetic
inactivation of its pharmacological target, Neiman–Pick C1-Like-1 (NPC1L1), or being fed
a diet that lacks phytosterols [36–38]. Conversely, feeding diets enriched in phytosterols
exacerbate phenotypes and results in sudden death [36,39].
Collectively, the available data indicates that the presentation of sitosterolemia in
both humans and rodent models is a function of the type and abundance of xenosterols
present in the diet that ultimately accumulates in plasma and tissues. This complicates
interpretations of ABCG5 ABCG8 physiology with respect to cholesterol metabolism, as
phytosterols are known to produce a myriad of biological effects, including disruptions of
sterol sensing by sterol receptor element binding protein 2 (SREBP-2), LXR, and the bile
acid receptor (farnesoid X receptor, FXR NR1H4) [40–43].
While sitosterolemia may present with normal or only modestly elevated plasma
cholesterol, cholesterol levels are generally lower in mice lacking functional G5G8 than
their wild-type counterparts. The precise mechanism accounting for this difference has not
been investigated but may be due to the paucity of ApoB containing lipoproteins in plasma
in mice compared to humans. An alternative explanation is a species difference in the role of
G5G8 in cholesterol absorption. Given its abundant expression in the intestinal epithelium,
its role in biliary cholesterol secretion, and the common pathway for cholesterol and
phytosterol absorption (NPC1L1), it stands to reason that G5G8 would oppose cholesterol
absorption. However, studies in both humans and mice have produced inconsistent
results. In both humans and mice, phytosterol absorption is clearly elevated [30,31,44,45].
Sitosterolemics appear on the higher end of the range for cholesterol absorption in humans,
a trait that maps to the ABCG5 ABCG8 locus [18,23]. However, the magnitude of the
increase is relatively modest compared to the increase in the absorption of phytosterols.
Mice lacking G5G8 do not show substantial increases in cholesterol absorption as assessed
by the dual isotope method [29,31]. When monitoring the appearance of radiolabeled sterol
in lymph, the absence of G5G8 either reduced or increased cholesterol absorption across
the intestinal epithelium [46–48]. Expression of a human transgene under the control of its
own promoter reduced fractional cholesterol absorption by 50% [49]. Consequently, the
role of G5G8 in cholesterol absorption remains unclear, and like other phenotypes, may
depend on dietary phytosterols.
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Deletion of G5G8 reduces biliary cholesterol secretion by 70–90%. Agents that
stimulate biliary cholesterol secretion are generally G5G8-dependent, including LXR
and FXR agonists, thyroid hormone, and choleretic agents (diosgenin, tauroursodeoxy-
cholate) [29,48,50–54]. Heterologous expression of Niemann–Pick C2 (NPC2) increases
biliary secretion of the protein and promotes G5G8-dependent biliary cholesterol secretion,
suggesting a role for this sterol-trafficking protein as a mediator of G5G8 activity or perhaps
as a source of, or acceptor for G5G8 substrates [55]. G5G8-independent biliary cholesterol
secretion is observed under some experimental conditions, including depletion and over-
expression of class B, type-1 scavenger receptor (SR-BI), infusion or feeding high levels of
cholate, ATP8B1 deficiency, and in lactating rats [29,56–60]. Some fraction of residual biliary
cholesterol secretion in the absence of G5G8 is likely mediated by detergent extraction. The
extent to which other enzymes contribute to a G5G8-independent pathway, and if such a
pathway might be targeted to increase biliary cholesterol secretion remains unknown.
3. Heterologous Expression of G5G8
The first ABCG5 ABCG8 transgenic strain contained an estimated 14 copies of the
human gene, increased biliary cholesterol concentrations five to six-fold, and reduced
susceptibility to experimental hypercholesterolemia and atherosclerosis [49,61]. A liver-
specific transgenic failed to protect mice from atherosclerosis unless combined with the
cholesterol absorption inhibitor ezetimibe [62,63]. The protective effects of G5G8 are pre-
sumably due to its role as the mediator of the final step of reverse cholesterol transport
(RCT). Pharmacological stimuli of RCT, including ezetimibe and LXR and FXR agonists,
require G5G8 to promote fecal neutral sterol loss and macrophage to feces RCT [50,64,65].
However, acute adenoviral-mediated overexpression of hepatic G5G8 fails to stimulate
macrophage to feces RCT [56]. Further, adenoviral expression of G5G8 paradoxically
increases plasma cholesterol, an effect blocked by ezetimibe [66]. This indicates that a
substantial amount of biliary cholesterol is reabsorbed in the small intestine and illustrates
the cooperative nature of hepatic and intestinal G5G8 in order to oppose hypercholes-
terolemia and promote RCT. This, however, is not the case for preventing phytosterolemia
as tissue-selective deletion of intestinal or hepatic G5G8 results in only modest elevations
in plasma phytosterols [67].
4. Beyond Phytosterols
Given the roles of G5G8 in opposing dietary sterol accumulation and biliary cholesterol
secretion, it is unsurprising that both rare and common variants have been associated
with plasma cholesterol, non-cholesterol sterols, low-density lipoprotein cholesterol (LDL-
C), and atherosclerotic and gallbladder disease across a large number of studies and
populations ([68–80], incomplete list). Other associations are intriguing and include insulin
resistance (G8:D19H) and type 2 diabetes (G5:G604E, G8:Y54C) and its renal complications
(G8:T400K) [81–83]. Mouse models of metabolic syndrome which lack leptin or its receptor
have diminished hepatic G5G8 and reduced biliary cholesterol secretion [66,84]. Rescue of
G5G8 in these models with chemical chaperones, adenoviral expression of the molecular
chaperone GRP78/binding immunoglobulin protein (BiP), or adenoviral expression of
G5G8 itself accelerates biliary cholesterol secretion, restores glycemic control, and reduces
plasma triglycerides [66,84,85]. Conversely, mice lacking G5G8 are more susceptible to diet-
induced obesity, insulin resistance, and hepatic steatosis when maintained on phytosterol-
free diets [86]. Collectively, these studies suggest an unappreciated relationship between
biliary cholesterol secretion, triglyceride metabolism, and insulin signaling. There also
appears to be a role for intestinal G5G8 in the absorption of triglycerides and chylomicron
assembly, which may influence metabolic phenotypes, but the underlying mechanism for
this phenotype remains unclear [46,47].
Independent of phytosterol accumulation, genome-wide association studies (GWAS)
and animal model data support an anti-atherosclerotic role for G5G8. This is presumably
due to the combined effects of limiting dietary cholesterol accumulation and promoting
Int. J. Mol. Sci. 2021, 22, 2641 5 of 15
RCT. Classically, the final steps of RCT are hepatobiliary secretion of neutral and acidic
sterols. However, disruptions in biliary cholesterol secretion do not result in concomitant
reductions in cholesterol excretion, indicating the presence of a compensatory, non-biliary
pathway which has been labeled transintestinal cholesterol elimination (TICE) [87]. Tissue-
specific deletion of G5G8 in the intestine reduced excretion of radiolabeled sterol from
the plasma compartment to feces, indicating a role for intestinal G5G8 in cholesterol
excretion [67]. The mediators of TICE and the relative contribution of G5G8 to intestinal
cholesterol excretion under a variety of pharmacological conditions remain to be fully
elucidated. These studies and the potential for therapeutic development have recently
been reviewed and are beyond the scope of this discussion [88,89].
5. Transcriptional Regulation of G5G8
ABCG5 ABCG8 is effectively a single gene with a common promoter that regulates
expression of both transcripts encoding each half of the transporter. To the best of our
knowledge, there are no reports of differential regulation of ABCG5 and ABCG8 transcripts.
Transcriptional regulation of ABCG5 ABCG8 by a small molecule LXR agonist (T0901317)
precipitated its discovery as the defective gene in sitosterolemia [22]. Expression of both
mRNA and protein increases in liver and intestine in response to small molecule LXR
agonists and dietary cholesterol, which promotes the accumulation of endogenous LXR
agonists, oxysterols (Figure 1 (7)) [22,29–31,49,90]. Liver receptor homolog 1 (LRH1), GATA
binding factor 4 (GATA-4), and hepatocyte nuclear factor 4α (HNF4α) binding sites map to
the 374 base pair intergenic promoter that separates the initiation codons for each protein,
the latter of which synergize with LXREs located in distal regions of the gene, to activate
the promoter and increase expression of both transcripts [91,92]
Hepatic expression of ABCG5 ABCG8 is also induced by FXR agonists and bile acids,
and where examined, in an FXR-dependent fashion (Figure 1 (7)) [54,93–95]. However,
regulation by bile acid FXR agonists is far more complicated. FXR-mediated activation
of ABCG5 ABCG8 requires fibroblast growth factor 15/19 (FGF15/19), which is itself an
FXR target gene that is secreted from the ileum in response to bile acids and promotes
Src-mediated phosphorylation of hepatic FXR, and FXR binding to the ABCG5 ABCG8
promoter [96]. FNDC5/Irisin is an FXR target gene that increases ABCG5 ABCG8 mRNA in
both the livers and intestines of transgenic mice, but the extent to which the endogenous
gene plays a role in ABCG5 ABCG8 regulation and sterol homeostasis mice or humans is not
known [97]. Whereas cholesterol and its metabolites tend to increase expression of ABCG5
ABCG8 mRNA, agonists for the constitutive androstane receptor (CAR) repress expression
of the transporter under conditions of elevated exogenous or endogenously-derived FXR
agonists [98,99].
Transcriptional regulation of ABCG5 ABCG8 by LXR and FXR fits well with its cen-
tral role in opposing the accumulation of excess cholesterol. Expansion of whole body
neutral and/or acid sterol pools increases expression [31,54,84,93,94,100,101]. Conversely,
blocking absorption of cholesterol or bile acids reduces expression in either liver or intes-
tine [37,101–103]. Less clear is the physiological benefit, if any, for alterations in ABCG5
ABCG8 expression by regulators of metabolism. Thyroid hormone increases ABCG5 ABCG8
mRNA, biliary cholesterol secretion, and fecal sterol excretion in both intact and hypophy-
sectomized rats [104]. Hepatic ABCG5 ABCG8 mRNA and protein are upregulated in the
absence of insulin signaling in mice, an effect attributed to disinhibition of Forkhead box
protein O1 (FOXO-1) [105,106]. The opposite was observed in a type 1 diabetic model
in rats [107]. The insulin-sensitizing drug, metformin, increased ABCG5 ABCG8 mRNA
and protein, an effect attributed to reduced period two occupancy of the ABCG5 ABCG8
promoter and disinhibition of gene expression [108]. Indeed, ABCG5 ABCG8 mRNA ex-
hibits a robust circadian rhythm at the transcriptional level (not observed for protein level,
unpublished observation) and hepatic ABCG5 ABCG8 mRNA and biliary cholesterol are
reduced in Bmal1-deficient mice [108,109]
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Alterations in ABCG5 ABCG8 expression have been reported by a variety of nutritional
cues, including upregulation in response elevated n-3 polyunsaturated fatty acids [110–112].
While upregulation of ABCG5 ABCG8 is generally observed in high fat diets containing
cholesterol and cholesterol-free, high fat diets, a single oral gavage of triacylglycerols
robustly repressed intestinal ABCG5 ABCG8 mRNA in mice [113]. In an independent study,
suppression of ABCG5 ABCG8 mRNA following high fat, high sucrose feeding was not
observed, but the diet used in this study contained both added cholesterol and cholate, and
thus hepatic cholesterol was increased five-fold compared to mice fed the control diet [114].
Diets containing high levels of sucrose robustly repressed expression of hepatic, but not
intestinal ABCG5 ABCG8 in rats [115]. Collectively, the data suggests that dietary repression
of ABCG5 ABCG8 may reflect reductions in the abundance of LXR and FXR agonists rather
than active repression by sucrose or triglyceride. Alternatively, differences across studies
may be associated with species and strain differences, both of which have been reported for
various ligands [116,117]. Diets supplemented with soy protein increased hepatic ABCG5
ABCG8 mRNA in rats [118]. The mechanisms for such an effect is not known but may
include modulation of the intestinal microbiota. Germ free mice exhibited elevations in
both intestinal and hepatic ABCG5 ABCG8 mRNA relative to specific pathogen free mice in
the absence and presence of ezetimibe [119]. Depletion of dietary iron upregulated hepatic
ABCG5 ABCG8 mRNA and promotes increased biliary cholesterol secretion [120]. Dietary
calcium supplementation was shown to increased intestinal ABCG5 ABCG8 mRNA and
fecal neutral sterol excretion in a hamster model of menopause [121].
Female biological sex has long been associated with increased biliary cholesterol.
Female mice had modest, but significant increases in biliary cholesterol and ABCG5 ABCG8
mRNA in the human transgenic strain [49]. Ovariectomy was subsequently shown to
reduce, and estrogen replacement to increase ABCG5 ABCG8 mRNA across the intestine in
independent strains of mice [116,122]. Diosgenin is a choleretic compound with estrogenic
properties that increases biliary cholesterol secretion. Its ability to increase biliary choles-
terol is largely G5G8-dependent, but reports on its impact on ABCG5 ABCG8 expression
are conflicting, showing no change in mice but an increase in both liver and intestine in
rats [54,123]
6. Post-Transcriptional Regulation
Less is known about the post-transcriptional regulation of the G5G8. The half trans-
porters are retained within the endoplasmic reticulum (ER) unless co-expressed [124,125].
Formation of the complex appears to be relatively inefficient in cultured cells, is dependent
upon the presence of N-linked glycans that reside in the third extracellular loop of each
protein, and can be enhanced by the expression of the lectin chaperones, Calnexin and
Calreticulin [124–127]. Using chimeric approaches, the ER-retention motif was localized to
the N-terminal, cytosolic domain, but has yet to be defined [128]. Failure to form complexes
within the ER results in rapid degradation of each half transporter [127,129]. At the cell
surface, the mature G5G8 complex resides within apical membranes of both hepatocytes
and enterocytes [124]. There is also evidence of an intracellular, recruitable pool of G5G8
that translocates to the canalicular surface in response to cAMP and in response to diets
containing cholate and cholesterol [114,130]. However, the stimuli and signaling pathways
involved in intracellular trafficking of G5G8 have yet to be elucidated.
A number of approaches have been utilized to investigate the activity of G5G8.
Heterologous expression in HEK293 and dog gall bladder epithelial cells demonstrated
G5G8-dependent cholesterol efflux to bile acid micelles, but not HDL or apolipoprotein
A1 [131,132]. Native mouse and recombinant human and mouse G5G8 have been purified
to varying degrees from liver, rat hepatocytes, Sf9 insect cells, and Pichia pastoris [133–136].
These studies demonstrated ATP- and magnesium-dependent, vanadate-sensitive ATPase,
and sterol transport activity. Various bile acids stimulate ATP hydrolysis. Among the
species tested, G5G8 activity was most sensitive to cholate [133]. Perhaps surprisingly,
neither cholesterol nor phytosterols stimulated ATPase or sterol transport activity in prepa-
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rations from Sf9 cells [135,136]. Using inside-out vesicles in this same system, Wang et al.
showed that other nucleotides could support sterol transfer, albeit less efficiently [135]
The nucleotide binding sites of G5G8 were proposed, and later confirmed by crystal-
lography, to be comprised of Walker A and B domains of one partner and the signature
motif of the other [137,138]. The Walker A and B domains of G8 juxtaposed to the signa-
ture motif of G5 were designated nucleotide binding site (NBS) 1. While both NBSs bind
8-Azido ATP, mutations in highly conserved residues within the Walker A and B domain
of G5 (NBS2), but not G8 (NBS1), abolished ATP binding and hydrolysis. These findings
were confirmed for G5G8-mediated biliary cholesterol secretion by expressing the mutants
in G5G8-defecient mice. Domain swapping experiments between G5 and G8 confirmed
that ATP hydrolysis in NBS2 is indispensable for activity [139]. G5G8 was crystallized as a
heterodimer in lipid bilayers (bicelles) in the presence of cholesterol in the nucleotide free
state to a resolution of four angstroms [138]. G5G8 was designated as a Type II Exporter.
Key molecular interactions inferred from this structure were validated as essential for
cholesterol transport in vivo by expressing recombinant mutants in G5G8-deficient mice.
Naturally occurring missense variants and mutants can provide mechanistic insight to pro-
tein structure–function. The potential impact of mutations and polymorphisms on G5G8
structure function inferred from the available crystal structure were recently reviewed [140].
However, formal investigations into the impact of missense variants of any type on G5G8
trafficking, stability, and activity have been limited to only a few.
7. Sitosterolemia and/or Familial Hypercholesterolemia
Challenges in the proper diagnosis of sitosterolemia include heterogeneity of the clinical
presentation of the disease, the lack of genotype–phenotype correlations, and the inability of
clinical laboratory assays to distinguish phytosterols from cholesterol [28,141,142]. Studies
among hypercholesterolemic subjects suggest sitosterolemia is significantly underdiag-
nosed [143,144]. Genome and exome sequence analysis of large populations indicates
that carriers of loss of function mutations are far more common than previously thought
and are at an elevated risk of coronary artery disease [72,80]. Exome sequence analysis
of over 60,000 individuals across multiple populations reveals 57 and 58 predicted loss of
function alleles for ABCG5 and ABCG8, respectively (https://gnomad.broadinstitute.org/
(accessed on 3 January 2021) v2.1.1) [145]. This analysis did not include missense variants,
37 of which have been described for sitosterolemia [141]. At the time of the preparation of
this review, 619 and 1307 missense variants have been catalogued in dbSNP for ABCG5
and ABCG8, respectively. Most are predicted to be benign, but virtually none of those
likely to be pathogenic or of uncertain significance have been experimentally or clinically
validated. The number of ABCG5 ABCG8 variants will undoubtedly grow as additional
genomes and exomes are sequenced, as will the need for better tools to predict which
variants are pathogenic.
An analysis of selected missense mutants of ABCG5 and ABCG8 suggests that the
majority of dysfunctional alleles are due to the inability of ABCG5 ABCG8 to heterodimerize
and traffic beyond the endoplasmic reticulum [127]. The development of correctors and
potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR, ABCC7,
OMIM: 602421) and the rescue of mutants of ABCB4, defective in progressive familial in-
trahepatic cholestasis type 3 (PFIC3, OMIM: 602347), suggest these or perhaps other small
molecule chaperones may facilitate maturation and rescue function of G5G8 [146,147]. How-
ever, no systematic approach to classify the types of mutations that cause sitosterolemia has
been made. We propose a draft of such a classification system for sitosterolemia (Table 1).
We based our initial draft on the system established for PFIC3 due to the fact that both
are biliary lipid transporters [148]. Our system may need future revision as additional
mutations are identified and the impact of these variants/mutants on G5G8 formation,
trafficking, and activity are determined. Nonetheless, this classification system provides a
framework for characterizing ABCG5 ABCG8 mutants that cause sitosterolemia and a basis
for the systematic investigation of compounds that may potentially rescue G5G8 function.
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Table 1. Classification system for experimentally verified sitosterolemia mutations.
Typical No Mutation ABCG5 ABCG8
Class I Nonsense, Frameshift, Deletions 57 known or predicted 58 known or predicted
Class II Maturation R389H, R419P, R419H, N437K R189H, P231T, R263Q, L501P, G574E, L596R
Class III Activity
Class IV Stability
Class V No Detectible Defect
Unclassified Inconclusive Results E146Q R543S, G574R
https://gnomad.broadinstitute.org/ (accessed on 3 January 2021) and Reference [127].
8. Conclusions and Future Directions
The last twenty years have revealed a great deal about the role of ABCG5 ABCG8
in cholesterol metabolism and in the defense against the accumulation of dietary xenos-
terols. The master regulators of neutral and acidic sterol metabolism modulate G5G8
abundance and activity as a component of the integrated machinery that maintains sterol
homeostasis. Much, however, remains unknown about the hormonal and intracellular sig-
nals that promote G5G8 translocation to the biliary surface and G5G8-mediated cholesterol
secretion. Beyond G5G8, the hepatocyte orchestrates the clearance of excess cellular choles-
terol by metabolism to bile acid or incorporation into very low density and high-density
lipoproteins, either on the surface of the particles or in the hydrophobic core following
esterification. What regulates and under what conditions does the intracellular flux of
cholesterol favor G5G8-dependent biliary secretion? Investigations of intestinal G5G8
regulation and activity have been more limited than in the liver. In what ways does the
regulation of G5G8 in the enterocyte differ, if any, from the hepatocyte? Targeting G5G8
to promote TICE is conceptually attractive to promote RCT, but studies have yet to re-
veal a route to a potential therapeutic and the molecular mechanisms that mediate TICE
remain elusive.
Sequencing of large numbers of genomes and exomes reveals that disease-causing
mutants in ABCG5 ABCG8 are significantly more common that previously appreciated.
The combination of the required instrumentation, expertise, and cost for routine clinical
laboratory analysis of plasma xenosterols is presently impractical. Conversely, genetic
screening has become substantially less costly and increasingly common across healthcare
systems. Genetic testing may offer a more practical means to identify and diagnose
sitosterolemics. Such an approach requires the cataloguing and inclusion of ABCG5 ABCG8
mutants among the various genetic testing platforms in use. A major limitation for such
an approach is the lack of validation of suspected and likely pathogenic variants that may
disrupt G5G8 function. Frameshift mutations in exon 13 of both ABCG5 and ABCG8 cause
sitosterolemia, indicating little tolerance for truncation of the protein. Thus, deletions or
frameshifts are expected to be Class I mutants. A significant number of splice donor and
acceptor variants have also been identified and are likely pathogenic, but have yet to be
formally analyzed. Of the 37 known missense variants, only 13 have been analyzed for
maturation. Although most failed to form mature complexes and have been designated
as Class II, three retained at least some degree of G5G8 maturation (G5:E146Q, G8:R543S,
G8:G574R). Future investigations of the structural and functional impact of these and other
missense mutants and variants will advance our understanding of sterol transport, the
molecular dynamics of the transporter, and potential therapeutics for sitosterolemia as well
as gall bladder and cardiovascular risk reduction.
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